SCHEMBL22368493

SCHEMBL22368493

CCOC(=O)C1C[C@H]2CN(Cc3ccccc3)C(=O)C2N1Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.44
▸ PKM P14618 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ KMT2A Q03164 4/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ CASP3 P42574 1/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ACE P12821 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20012750 1.00 ALDH1A1 (0.44) ALDH1A1PKMNPSR1HSD17B10KMT2A
SCHEMBL22368490 1.00 ALDH1A1 (0.44) ALDH1A1PKMNPSR1HSD17B10KMT2A
SCHEMBL21088072 1.00 ALDH1A1 (0.44) ALDH1A1PKMNPSR1HSD17B10KMT2A
SCHEMBL9749200 0.80 ALDH1A1 (0.48) ALDH1A1PKMNPSR1KMT2AMEN1
SCHEMBL31432992 0.80 ALDH1A1 (0.48) ALDH1A1PKMNPSR1KMT2AMEN1
SCHEMBL18396791 0.80 ALDH1A1 (0.48) ALDH1A1PKMNPSR1KMT2AMEN1
SCHEMBL18397552 0.77 MEN1 (0.46) ALDH1A1PKMNPSR1KMT2AMEN1
SCHEMBL4798833 0.77 CYP3A4 (0.53) ALDH1A1PKMNPSR1HSD17B10KMT2A
SCHEMBL9344776 0.76 ALDH1A1 (0.45) ALDH1A1PKMNPSR1HSD17B10KMT2A
SCHEMBL20328794 0.76 PKM (0.46) ALDH1A1PKMNPSR1HSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3698796-B1 PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS NOVARTIS AG (CH) 2021-10-27 — — EP disclosed
EP-3698796-A1 PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS Novartis AG (CH) 2020-08-26 — — EP disclosed
Send feedback